Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Vaccines
Filter     Order     Display # 
Date Item Title
20 Aug 2007 Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis
18 Aug 2007 Dendreon announces publication of Phase 1 study highlighting immunologic and clinical activity of Lapuleucel-T (Neuvenge(R)) in advanced breast cancer patients
16 Aug 2007 VGX Pharmaceuticals Announces Initiation of IND-enabling Toxicology Studies
15 Aug 2007 Application for Rotarix(R) by AVANT's partner, GlaxoSmithKline, is accepted for review by the FDA
15 Aug 2007 Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1)
09 Aug 2007 Iomai trial shows 100 percent immune response in elderly subjects vaccinated with novel travelers' diarrhea patch vaccine
09 Aug 2007 MOLOGEN AG: Treatment permission granted for cancer therapy in India
09 Aug 2007 Biomira and Merck KGaA sign amended and restated collaboration and supply agreements related to Stimuvax(R)
05 Aug 2007 ImmunoCellular Therapeutics Updates Brain Tumor Vaccine Program Status; First Three Patients Enrolled
02 Aug 2007 Iomai Vaccine Confers Statistically Significant Protection Against Travelers' Diarrhea in Phase 2 Study
01 Aug 2007 Novavax Begins Human Clinical Testing of Novel Pandemic Flu Vaccine
31 Jul 2007 AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine
31 Jul 2007 Alphavax announces interim results from Phase 1 influenza vaccine clinical trial
26 Jul 2007 Oxford Biomedica announces data safety monitoring board recommendation to continue TroVax (R) Phase III trial in renal cancer as planned
24 Jul 2007 Nventa announces publication of final results of Phase 2 study of hspe7 un Cervical Dysplasia
24 Jul 2007 IDM Pharma Announces Plans to Amend New Drug Application for Mifamurtide (L-MTP-PE) for the Treatment of Patients with Osteosarcoma
24 Jul 2007 Baxter Announces Preliminary Phase I/II Data for Seasonal Influenza Vaccine Candidate
20 Jul 2007 Affiris begins clinical testing of Alzheimer's vaccine
19 Jul 2007 Orchestra Therapeutics discontinues its HIV vaccine development program
19 Jul 2007 TechnoVax Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate
19 Jul 2007 Publication of VIR201 Phase IIa trial results in peer reviewed scientific journal
18 Jul 2007 GeoVax Announces Start of 2 New HIV/AIDS Vaccine Human Trials
18 Jul 2007 Acambis' universal influenza vaccine enters Phase 1 trial
13 Jul 2007 Dynavax Completes Enrollment of HEPLISAV(TM) Phase 3
12 Jul 2007 Geron initiates clinical trial of Telomerase cancer vaccine in patients with acute myelogenous leukemia
12 Jul 2007 Clinical Development Update
11 Jul 2007 Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
10 Jul 2007 Novavax Licenses Wyeth's Virus-Like Particle Technology
04 Jul 2007 Cytos Biotechnology reports results from phase IIa study with CYT003-QbG10 in patients suffering from atopic dermatitis
04 Jul 2007 MedImmune Begins Dosing Children Six Months to 24 Months of Age in Phase 1 Study of Vaccine to Help Prevent Two of the Most Common Viral Causes of Childhood Respiratory Illness
03 Jul 2007 DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC(TM)
03 Jul 2007 Novartis enhances its vaccine pipeline by gaining access to Intercell's key technologies and vaccines programs
28 Jun 2007 AVANT's Partner, GlaxoSmithKline, Files Rotarix(R) Application for U.S. Marketing Approval with the FDA
27 Jun 2007 Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
22 Jun 2007 Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin(TM) for Multiple Sclerosis
22 Jun 2007 First ad35-based HIV-1 vaccine enters Phase I clinical trial at the NIH
19 Jun 2007 New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
19 Jun 2007 Phase I for Influenza vaccine adjuvanted with Intercell’s IC31(TM) started
19 Jun 2007 Diamyd diabetes study invalidated
18 Jun 2007 Hypertension vaccine CYT006-AngQb achieves strong blood
14 Jun 2007 GlaxoSmithKline's application for DTaP-IPV vaccine is accepted for review by the FDA
14 Jun 2007 Novartis gains European approval for its innovative flu vaccine Optaflu(R)
12 Jun 2007 Orchestra Therapeutics announces new Phase II clinical data on NeuroVAX (TM) demonstrating marked expansion of regulatory T Cell populations in patients with multiple sclerosis
12 Jun 2007 Opexa Presents Tovaxin(TM) Research at Federation of Clinical Immunology Societies Annual Meeting
08 Jun 2007 Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
07 Jun 2007 All patients are enrolled in Curalogic’s clinical EU phase III trial with the ragweed product
06 Jun 2007 Coley Pharmaceutical Group's Vaccine Adjuvant, VaxImmune, to Enter Phase III Clinical Testing as Part of GlaxoSmithKline's Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer
06 Jun 2007 IDM Pharma Presents Preliminary Results from Phase II UVIDEM(R) Melanoma Vaccine Clinical Trial
06 Jun 2007 Encouraging clinical activity of GSK's novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
05 Jun 2007 Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 201 - 250 of 601

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Toll-Like Receptor (TLR) Agonists & Antagonists

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics